Videos

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, discusses the results of a phase III study comparing the efficacy of eribulin mesylate to capecitabine in patients with locally advanced or metastatic breast cancer.

Treating estrogen receptor–positive breast cancer without sparking resistance is a complex endeavor that should involve simultaneously targeting the hormone-signaling and PI3 kinase molecular pathways

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, discusses results from the international ATLAS study that was presented at the 2012 San Antonio Breast Cancer Symposium.

Circulating tumor cell counts can provide a variety of useful information for clinicians treating patients with metastatic breast cancer.

A retrospective study of older women with early-stage breast cancer who received adjuvant trastuzumab alone or in combination with anthracyclines has revealed a higher incidence of heart failure and cardiomyopathy.

An interview with Jenny C. Chang, MB BChir, MD, who broke new ground in cancer research when she identified and patented a 493-gene signature for breast cancer.

Carlos L. Arteaga, MD, from Vanderbilt-Ingram Cancer Center, describes key takeaway points for practicing oncologists, clinical investigators, and scientists from the 2012 SABCS.

The mental toll and stress of a breast cancer diagnosis might factor into the cognitive impairment experienced during chemotherapy treatment, commonly referred to as "chemo brain."

Christopher Twelves, MD, discusses results from a phase III trial that compared capecitabine to eribulin mesylate in women with metastatic breast cancer.

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, discusses research into clinically targetable genetic alterations in patients with triple-negative breast cancer.

Long-term follow-up results showed that the hypofractionated regimens were as effective as the 50-Gy standard in women with early-stage breast cancer.

Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.

John Yarnold, MBBS, from The Institute of Cancer Research in London, discusses results from the START trials that examined hypofractionated radioatherapy for women with early breast cancer.

Patients with triple-negative breast cancer had no statistically significant improvement in disease-free survival when they received adjuvant treatment with chemotherapy plus 1 year of bevacizumab.

Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.

Eribulin mesylate failed to show a statistically significant survival benefit compared with capecitabine in women with previously treated metastatic breast cancer.

Patients with triple-negative breast cancer who have residual disease after receiving neoadjuvant chemotherapy have a series of genetic alterations that are clinically targetable and may warrant further study.

Kapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.

Stefan Aebi, MD, from the Luzerner Kantonsspital, Switzerland, discusses findings from the CALOR trial that examined the administration of adjuvant chemotherapy for women recurrent breast cancer.

Preliminary research suggests that in-vitro exposure to an HDAC inhibitor may sensitize triple-negative breast cancer cells to treatment with a PARP inhibitor and cisplatin.

Adjuvant chemotherapy improved survival rates in women with isolated local or regional breast cancer recurrence, according to results from the CALOR trial.

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Sentinel lymph node surgery may provide a less-invasive alternative to axillary lymph node dissection for nodal staging in node-positive breast cancer.

Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.

Judy C. Boughey, MD, from the Mayo Clinic in Rochester, MN, discusses surgical techniques examined in the Z1071 study that could help minimize the false negative rates experienced with SLN surgery.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.

For the past 10 years, Matthew J.C. Ellis, MB BChir, PhD, has focused his research on exploring the breast cancer genome in partnerships with academic and government-funded centers in the United States and the United Kingdom.

The clinical subtyping of breast cancer appears to be coming into a golden era as an increased understanding of subtyping promises to help advance treatments and outcomes for patients.

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, compares results from two trials analyzing the mTOR inhibitors temsirolimus and everolimus in breast cancer.